|
Canada-0-READAPTATION 公司名錄
|
公司新聞:
- Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 394 No 12)
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Zorevunersen in Children and Adolescents with Dravet Syndrome | New . . .
Dravet syndrome is a severe developmental and epileptic encephalopathy caused primarily by SCN1A haploinsufficiency Risks of sudden unexpected death in epilepsy and cognitive deficits are higher a
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Cabotegravir plus Rilpivirine for Persons with HIV and Adherence . . .
Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking We con
- Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Clinical Practice Topics | The New England Journal of Medicine
The New England Journal of Medicine NEJM Clinician NEJM Evidence NEJM AI NEJM Catalyst
- A Randomized Trial of Tenecteplase in Acute Central Retinal Artery . . .
Central retinal artery occlusion can result in permanent vision loss Effective treatment is lacking We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving adul
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide | New . . .
Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer
- Fish-Oil Supplementation and Cardiovascular Events in Patients . . .
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited Supplementation with n−3 polyunsaturated fatty acids
|
|